DUBLIN, September 20, 2021--(BUSINESS WIRE)--The "Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.
The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is projected to grow at a modest CAGR of 3.5% during the forecast period (2020-2026).
The key aspect that drives the growth of the market includes the rising incidences of diabetes particularly type 2 among the people across the globe. The prevalence of diabetes in 2019 across the globe was more than 463 million and is projected to increase over the forecast period as per the International Diabetes Federation (IDF)'s projections.
The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body. Hence, such factors are likely to enhance the growth of the market over the forecast period. However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market.
The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type. Based on the drug type, the market is segmented as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others.
Amongst these drug types of the global dipeptidyl peptidase 4 (DPP-4) inhibitors, the Sitagliptin and Saxagliptin are projected to hold the most lucrative share in the market. Geographically, the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is anticipated to grow considerably over the forecast period.
Further, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp., and Takeda Pharmaceutical Co. among others are some of the prominent players functioning in the global dipeptidyl peptidase 4 (DPP-4) inhibitors market.
New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.
Key Topics Covered:
1. Report Summary
Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Industry
Recovery Scenario of Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Merck & Co.
3.3.2. Novartis AG
3.3.3. Eli Lily &Co.
3.3.4. Boehringer Ingelheim International GmbH
4. Market Determinants
5. Market Segmentation
5.1. Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market by Drug Type
6. Regional Analysis
6.1. North America
6.1.1. United States
6.2.6. Rest of Europe
6.3.5. South Korea
6.3.6. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AstraZeneca Plc
7.2. Boehringer Ingelheim International GmbH
7.3. Bristol Myers Squibb Co.
7.4. Eli Lily & Co.
7.5. GlaxoSmithKline Plc
7.6. Kowa Co. Ltd.
7.7. LG Life Sciences Ltd.
7.8. Merck & Co.
7.9. Novartis AG
7.10. Pfizer Inc.
7.11. Phenomix Corp.
7.12. Sanofi SA
7.13. Sanwa Kagaku Kenkyusho Co. Ltd.
7.14. SatRx LLC
7.15. Takeda Pharmaceutical Co.
For more information about this report visit https://www.researchandmarkets.com/r/ijt7nb
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005656/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900